In order for gene therapy of the hemoglobinopathies to become a reality, gene transfer must be developed that are capable of high-level expression, that can efficiently transduce hematopoietic stem cells, and do not cause disease. The goal of this project is to perform studies relevant to these three challenges.
Specific Aim 1 is directed toward our continued investigations of chromatin insulators, elements that can increase both the expression and possibly the safety of gene transfer vectors. This includes testing the activity of a prototypic insulator in a primate transplantation model, and cloning and characterizing new chromatin insulators.
Specific Aim 2 is directed toward characterizing new chromatin insulators.
Specific Aim 2 is directed toward characterizing the sites of vector integration in clinically, relevant hematopoietic cells, with a special emphasis on identifying any preference for open chromatin, a unique chromosomal structure associated with active genes.
Specific Aim 3 is directed toward characterizing the properties of virus vectors for globin gene available now and to be developed by the Program Project participants, in a clinically relevant primate transplantation model. This includes vectors base on a variety of recombinant viruses such as oncoretroviruses, lentiviruses, foamy viruses, and hybrid adeno / adeno-associated viruses. Combined with the other Projects of this Program Project, these specific aims will improve both the safety and efficacy of recombinant virus vectors for globin genes, and provide critical insights into the potential risks and benefits of these vectors prior to their use in clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL053750-14
Application #
7488341
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Project Start
Project End
Budget Start
2007-09-01
Budget End
2008-08-31
Support Year
14
Fiscal Year
2007
Total Cost
$329,722
Indirect Cost
Name
University of Washington
Department
Type
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Constantinou, Varnavas C; Bouinta, Asimina; Karponi, Garyfalia et al. (2017) Poor stem cell harvest may not always be related to poor mobilization: lessons gained from a mobilization study in patients with ?-thalassemia major. Transfusion 57:1031-1039
Gori, Jennifer L; Butler, Jason M; Kunar, Balvir et al. (2017) Endothelial Cells Promote Expansion of Long-Term Engrafting Marrow Hematopoietic Stem and Progenitor Cells in Primates. Stem Cells Transl Med 6:864-876
Psatha, Nikoletta; Karponi, Garyfalia; Yannaki, Evangelia (2016) Optimizing autologous cell grafts to improve stem cell gene therapy. Exp Hematol 44:528-39
Li, Li B; Ma, Chao; Awong, Geneve et al. (2016) Silent IL2RG Gene Editing in Human Pluripotent Stem Cells. Mol Ther 24:582-91
Karponi, Garyfalia; Psatha, Nikoletta; Lederer, Carsten Werner et al. (2015) Plerixafor+G-CSF-mobilized CD34+ cells represent an optimal graft source for thalassemia gene therapy. Blood 126:616-9
Vierstra, Jeff; Reik, Andreas; Chang, Kai-Hsin et al. (2015) Functional footprinting of regulatory DNA. Nat Methods 12:927-30
Qi, Heyuan; Liu, Mingdong; Emery, David W et al. (2015) Functional validation of a constitutive autonomous silencer element. PLoS One 10:e0124588
Liu, Mingdong; Maurano, Matthew T; Wang, Hao et al. (2015) Genomic discovery of potent chromatin insulators for human gene therapy. Nat Biotechnol 33:198-203
Polak, Paz; Karli?, Rosa; Koren, Amnon et al. (2015) Cell-of-origin chromatin organization shapes the mutational landscape of cancer. Nature 518:360-364
Watts, Korashon L; Beard, Brian C; Wood, Brent L et al. (2014) No evidence of clonal dominance after transplant of HOXB4-expanded cord blood cells in a nonhuman primate model. Exp Hematol 42:497-504

Showing the most recent 10 out of 161 publications